Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03795025
Other study ID # Trainome 2019#014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 8, 2019
Est. completion date March 12, 2020

Study information

Verified date May 2020
Source Inland Norway University of Applied Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to validate the use of contralateral designs in studies of effects of resistance exercise. It will recruit healthy young (18-35 years) individuals, which will be allocated to 4 experimental groups. In two of the experimental groups, 3x10 or 6x10 repetitions of heavy resistance exercise on one leg will be combined with no training of the other leg for 7 weeks. In the third group, 3x10 repetitions of heavy resistance exercise on one leg will be combined with 6x10 repetitions of heavy resistance exercise on the other leg for 7 weeks. In the fourth group, which serves as a control group, a period of no training (similar in length to the training period of groups 1-3; 7 weeks), before both legs will train 3x10 repetitions of heavy resistance exercise in an unilateral manner.


Description:

Our understanding of how exercise affects muscular adaptations at the cellular and molecular level comes from the use of skeletal muscle biopsies. Such studies are met by several challenges, including its invasive nature, costs of muscle analyses, large inter-participant variability in response to exercise and a limited number of subjects (related to ethical concerns regarding exposing participants to biopsies). Consequently, studies often include small sample sizes, resulting in low statistical power. This poses a great challenge to the field of exercise physiology. While increasing sample size may not always be feasible, employing alternative designs may offer a way to increase the statistical power. An example of such a design is the so-called cross-over design, wherein participants serve as their own control thereby reducing the inter-participant variation. An interesting variant of the cross-over design is the unilateral or contralateral exercise model. In such designs, each of the participant's limbs (e.g. legs) are randomly allocated to perform different types of training/treatments in close temporal proximity. This design obliterates the need for a wash-out period and removes the potential effects of confounding factors such as diet, activity and sleep decreases. Thus, resources, time spent and variability can be reduced. However, validation of such studies is lacking.

In an effort to validate a contralateral training design, the investigators will recruit young (18-35 years) healthy individuals to 4 groups performing unilateral progressive strength training; (1) one leg with no training and one leg with 3x10 maximal repetitions, (2) one leg with no training and one leg with 6x10 maximal repetitions, (3) one leg with 3x10 maximal repetitions and one leg with 6x10 maximal repetitions and (4) a control group with an initial period of no training (similar in length to the training period of groups 1-3) followed by a period of 3x10 maximal repetitions on each leg. Leg training will consist of one-legged leg press and one-legged knee extensions. All groups, except the control group (during the no-training control period), will train the upper body by 3x10 maximal repetitions in bench press and lying rowing. Prior to the 7 week training intervention, all four groups will go through a 3-week period of familiarization to training and repeated testing (4 test time points for performance measures).

This design allows us to investigate the benefits of a contralateral design compared to the more common two-group design, the intra-individual variation vs the inter-individual variation, the potential contralateral effect of training one leg on the physiology and functional abilities of the non-trained leg, and whether or not these perspective are affected by training volume. We will also investigate whether participant classification into low or high responders is universal across several measures of muscle mass and strength, and between different training volumes. Further, by measuring several hypertrophy-related outcomes (e.g. changes in ribosome volume, activation of satellite cells and transcriptional changes), the investigators will extend previous findings regarding the effects of training volume on these variables and their ability to predict training outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date March 12, 2020
Est. primary completion date March 12, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Healthy

Exclusion Criteria:

- Smoking

- Strength training more than 2 times per months for the last 6 months

- Endurance training more than 3 hours per week

- Adverse reactions to lidocaine

- Consumption of supplements or medication affecting muscular adaptations to strength training

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Strength training 3x10RM + no training
Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg does not exercise.
Strength training 6x10RM + no training
Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 6 sets of 10 maximal repetitions, the other leg does not exercise.
3x10RM + 6x10RM
Progressive unilateral strength training 3 times per week for 3 + 7 weeks. One leg exercises with 3 sets of 10 maximal repetitions, the other leg exercises with 6 sets of 10 maximal repetitions.

Locations

Country Name City State
Norway Inland Norway University of Applied Sciences Lillehammer

Sponsors (2)

Lead Sponsor Collaborator
Inland Norway University of Applied Sciences University of Birmingham

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Muscle fiber area Muscle cell cross-sectional area measured in biopsies from m. vastus lateralis using immunohistochemistry Changes over the course of the intervention (0-10 weeks)
Secondary Body mass composition Body mass composition measured using Dual-energy X-ray absorptiometry (DXA) Changes over the course of the intervention (0-10 weeks)
Secondary Rate of muscle protein synthesis (%/day) By ingesting deuterium we will label alanine to measure the rate of its incorporation into muscle proteins. This is done by collection of blood before, during and after, and a biopsy 3 days after deuterium ingestion to be analyzed with chromatography and mass spectrometry. Results will be reported as a rate of synthesis in %/day. Mesured over 3 days in week 7 of the study
Secondary M. vastus lateralis thickness M. vastus lateralis thickness mesured by ultrasound Changes over the course of the intervention (0-10 weeks)
Secondary Unilateral leg press strength (1RM test) The ability of muscles of the lower body to exert maximal force during dynamic movements in a leg press Changes over the course of the intervention (0-10 weeks)
Secondary Unilateral knee extension strength (1RM test) The ability of muscles of the lower body to exert maximal force during dynamic movements in a knee extension Changes over the course of the intervention (0-10 weeks)
Secondary Barbell bench press muscle strength (1RM test) The ability of muscles of the upper body to exert maximal force during dynamic movements in a bench press Changes over the course of the intervention (0-10 weeks)
Secondary Lying rowing muscle strength (1RM test) The ability of muscles of the upper body to exert maximal force during dynamic movements in a lying row exercise Changes over the course of the intervention (0-10 weeks)
Secondary Unilateral lower body isokinetic muscle strength at 60 and 240 deg per second in a mechanical dynamometer (Humac NORM) The ability of muscles of the lower body to exert maximal force during isokinetic movements Changes over the course of the intervention (0-10 weeks)
Secondary Unilateral lower body isometric muscle strength in a mechanical dynamometer (Humac NORM) The ability of muscles of the lower body to exert maximal force during isometric contractions Changes over the course of the intervention (0-10 weeks)
Secondary One-legged cycling Performance indicies measured during an incremental one-legged cycling test Changes over the course of the intervention (0-10 weeks)
Secondary Muscle phenotype Muscle fiber type composition measured in biopsies from m. vastus lateralis using immunohistochemistry Changes over the course of the intervention (0-10 weeks)
Secondary Muscle cell biological traits Muscle cell biological traits, including numbers of myonuclei, satelitte cells and capillaries, measured in biopsies from m. vastus lateralis using immunohistochemistry Changes over the course of the intervention (0-10 weeks)
Secondary Gene expression in skeletal muscle RNA (e.g. messenger RNA, ribosomal RNA, microRNA, long non-coding RNA) abundances in m. vastus lateralis, measured both as single genes and at the level of the transcriptome Changes over the course of the intervention (0-10 weeks)
Secondary Protein abundances in skeletal muscle measured by western blot Levels of proteins and their modification status (e.g. phosphorylation) in m. vastus lateralis, measured at the level of single proteins and at the level of the proteome Changes over the course of the intervention (0-10 weeks)
Secondary Hormones in blood Levels of hormones in blood Changes over the course of the intervention (0-10 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1